Spero Therapeutics, Inc.
SPRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $56 | $77 | $65 | $495 |
| - Cash | $53 | $76 | $109 | $113 |
| + Debt | $4 | $6 | $7 | $7 |
| Enterprise Value | $7 | $7 | -$37 | $389 |
| Revenue | $48 | $104 | $49 | $3 |
| % Growth | -53.8% | 113.6% | 1,482.4% | – |
| Gross Profit | -$49 | $52 | $49 | $3 |
| % Margin | -101.7% | 50.4% | 100% | 100% |
| EBITDA | -$72 | $27 | -$43 | -$87 |
| % Margin | -151.1% | 26.2% | -88.4% | -2,839.4% |
| Net Income | -$69 | $23 | -$46 | -$90 |
| % Margin | -142.9% | 22% | -95.5% | -2,923.6% |
| EPS Diluted | -1.27 | 0.43 | -1.23 | -2.91 |
| % Growth | -395.3% | 135% | 57.7% | – |
| Operating Cash Flow | -$23 | -$33 | -$8 | -$64 |
| Capital Expenditures | $0 | $0 | $0 | $64 |
| Free Cash Flow | -$23 | -$33 | -$8 | $0 |